Umbilical Cord Stem Cells for Skin Grafts in Donor Site Wounds

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

88 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-20

Study Completion Date

2026-10-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate the safety and effectiveness of human umbilical cord mesenchymal stem cell (hUCMSC) therapy in patients undergoing medium-thickness skin grafts for donor site wounds. The study aims to answer the following main questions:

* Question 1: Does hUCMSC therapy improve the healing quality and speed of donor site wounds in comparison to standard treatment?
* Question 2: Does hUCMSC therapy reduce scar formation in the donor site wounds?

Participants in this study will undergo medium-thickness skin grafts, and those in the treatment group will receive hUCMSC therapy. The main tasks for participants will involve regular follow-up visits, monitoring of wound healing progress, and assessment of any potential side effects or complications associated with the therapy.

In order to evaluate the effectiveness of hUCMSC therapy, researchers will compare the treatment group receiving hUCMSC therapy with a control group that receives standard treatment alone. The aim is to determine if the use of hUCMSC therapy leads to improved healing outcomes and reduced scar formation compared to the standard treatment group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Umbilical Cord Mesenchymal Stem Cells for the Repair of Large Area Burn Wounds

NCT06122532

Large Area Burns

NOT_YET_RECRUITING NA

Allogenic Stem Cell Therapy in Patients With Acute Burn

NCT01443689

Burns

UNKNOWN PHASE1/PHASE2

Safety and Exploratory Efficacy Study of Collagen Membrane With Mesenchymal Stem Cells in the Treatment of Skin Defects

NCT02672280

Wounds Diabetic Foot Ulcers Burns

UNKNOWN PHASE1/PHASE2

Autologous Adipose Stem Cell Assisted Skin Graft

NCT04532593

Skin Graft

UNKNOWN NA

The Improving Effect of Autologous Stromal Vascular Fraction (SVF) in Adipose Tissue on Skin Grafting

NCT02546882

Skin; Deformity, Due to Scar

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The donor site of the medium-thickness skin graft procedure usually forms scars or even hypertrophic scars, which significantly differ from normal skin physiology and cause discomfort to patients such as itching and burning sensations. Currently, the pathological mechanism of scar formation is not fully understood. There is a pressing clinical need for new methods to improve the healing quality and speed of donor site wounds in patients undergoing medium-thickness skin grafts and to reduce scar formation.

It is well known that various types of stem cells from different sources are involved in the process of wound repair. Under the regulation of various signaling molecules and chemotactic factors, they migrate to the wound, proliferate, and differentiate into various cellular components of the skin, thus constructing new tissue structures and achieving wound healing. Stem cells possess powerful self-renewal and multi-directional differentiation abilities. Some stem cells have been successfully applied in the treatment of severe burn wounds and non-healing wounds, yielding promising results.

Furthermore, in recent years, tissue engineering techniques have been used to combine stem cells with appropriate scaffolds to create tissue-engineered skin, utilizing the potential of stem cells for multi-directional differentiation and rapid expansion. This approach allows for rapid coverage and functional reconstruction of large-area wounds. Therefore, we also hope to enhance the healing quality of donor site wounds in patients undergoing medium-thickness skin grafts and inhibit excessive scar formation by utilizing stem cell technology.

Among the various options, the use of human umbilical cord mesenchymal stem cells (UCMSC) is highly feasible for treating donor site wounds in medium-thickness skin graft procedures. UCMSC has abundant sources, easy collection, easy expansion, no harm to donors, no ethical controversies, potential for industrialization and standardized clinical treatment, and excellent biological characteristics.

This study aims to investigate the safety and efficacy of human umbilical cord mesenchymal stem cell (hUCMSC) therapy for donor site wounds in medium-thickness skin grafts, as well as its effect in reducing scar formation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Wound Scar, Hypertrophic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

The efficacy evaluation component is conducted in a blinded manner, meaning that the assessors of efficacy outcomes are composed of plastic surgeons who are not members of the research team, have not participated in the intervention, and are unaware of the group allocation of the patients.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

human umbilical cord mesenchymal stem cells

Injection of human umbilical cord mesenchymal stem cells (hUCMSC) into the donor site.

1. Dosage of stem cell preparation: Calculated based on the area of the donor site, with a cell count of 1X10\^5cells/cm2.
2. Administration method: The cells are prepared as an injectable suspension using a blank solvent for stem cells at a concentration of 1X10\^6 cells/ml (0.1 ml/cm2).
3. Timing of administration: Administered immediately after completion of the donor site harvesting procedure.
4. Treatment duration: The stem cell administration is a single dose, administered at the specified timing as described above

Group Type EXPERIMENTAL

human umbilical cord mesenchymal stem cells

Intervention Type PROCEDURE

After the completion of the donor site harvesting in the experimental group, allogeneic umbilical cord mesenchymal stem cells are injected into the deep layer of the de-epithelialized area and the surrounding 0.5cm subcutaneous region. After the injection, the wound is covered and dressed with conventional dressings.

blank solvent

Injection of an equal volume of blank solvent for suspension of stem cells into the donor site.

1. Dosage of Control group preparation: Calculated based on the area of the donor site.
2. Administration method: Injection of an equal volume of blank solvent for suspension of stem cells into the donor site.
3. Timing of administration: Administered immediately after completion of the donor site harvesting procedure.
4. Treatment duration: The Control group administration is a single dose, administered at the specified timing as described above

Group Type PLACEBO_COMPARATOR

blank solvent

Intervention Type PROCEDURE

After the completion of the donor site harvesting in the experimental group, the de-epithelialized area and the surrounding 0.5cm subcutaneous region is injected an equal volume of blank solvent for stem cell suspension in the control group. After the injection, the wound is covered and dressed with conventional dressings.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

human umbilical cord mesenchymal stem cells

After the completion of the donor site harvesting in the experimental group, allogeneic umbilical cord mesenchymal stem cells are injected into the deep layer of the de-epithelialized area and the surrounding 0.5cm subcutaneous region. After the injection, the wound is covered and dressed with conventional dressings.

Intervention Type PROCEDURE

blank solvent

After the completion of the donor site harvesting in the experimental group, the de-epithelialized area and the surrounding 0.5cm subcutaneous region is injected an equal volume of blank solvent for stem cell suspension in the control group. After the injection, the wound is covered and dressed with conventional dressings.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients between 18 and 60 years old with extensive scars, large benign tumors, or fresh wounds on the body surface.
2. Patients who undergo medium-thickness skin graft surgery (donor site can be from the thigh, abdomen, or back).
3. Participants who have a thorough understanding of the study objectives, significance, implementation plan, potential benefits, risks involved, measures to address risks, and the rights and obligations of the subjects (including privacy protection and the right to withdraw), and are willing to participate in this clinical study and can cooperate effectively.

Exclusion Criteria

Participants who meet any of the following criteria are not suitable for inclusion:

1. Hypertension, hypotension, heart disease (including history of myocardial ischemia, coronary heart disease, myocarditis).
2. Liver or kidney dysfunction.
3. Infectious diseases (including viral hepatitis, syphilis, HIV/AIDS, etc.).
4. Venous thrombosis, thoracic or abdominal aortic aneurysm, aortic dissection.
5. Blood disorders (abnormal coagulation function, anemia, leukemia, polycythemia vera, aplastic anemia, etc.).
6. Allergic conditions (urticaria, bronchial asthma, history of allergic reactions to two or more drugs or foods).
7. Respiratory system diseases (chronic bronchitis, emphysema, bronchiectasis, respiratory failure, chronic obstructive pulmonary disease, interstitial pneumonia).
8. Digestive system diseases (severe gastric or duodenal ulcers, chronic gastritis, chronic pancreatitis).
9. Urinary system diseases (chronic urinary tract infections, nephritis, nephrotic syndrome).
10. Endocrine system diseases (hyperthyroidism, diabetes, acromegaly, pituitary diseases, adrenal diseases, diabetes insipidus).
11. Organic neurological disorders or psychiatric illnesses (encephalitis, sequelae of traumatic brain injury, epilepsy, schizophrenia, hysteria, depression, severe insomnia, neurasthenia).
12. Chronic skin diseases (especially infectious, allergic, and inflammatory systemic skin diseases, such as extensive eczema, pemphigus, pemphigoid).
13. Autoimmune diseases and collagen diseases (such as systemic lupus erythematosus, dermatomyositis, scleroderma).
14. History of long-term smoking, alcohol abuse, or drug addiction.
15. History of major surgeries (such as gastric, lung, splenic, renal, or liver resection).
16. History of other significant malignant tumors.
17. Blood donation or organ transplantation within the past 5 years.
18. Pregnancy, lactation, menstrual period, or within 1 year after termination of pregnancy.
19. Previous circumstances of being rejected for voluntary blood donation.
20. Other situations deemed unsuitable for participation in this study by the investigators.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes